Target intelligence / Profile preview

Gastrointestinal mucosa and mucoproteins

Molecular classification
Other (mucosa: tissue type), Glycoprotein (mucoproteins/mucins)
01

Overview

The **gastrointestinal mucosa** is a complex mucous membrane layer lining the digestive tract, composed of epithelial cells, connective tissue, and smooth muscle, responsible for absorption, secretion, and barrier functions[5][6]. **Mucoproteins** (primarily mucins such as MUC2) are highly glycosylated proteins secreted by goblet cells that form the structural framework of the mucus layer, providing a crucial barrier to pathogens, physical injury, and facilitating lubrication[2][3][4][6][7]. The mucus and underlying mucosa play essential roles in immune defense, maintaining a beneficial microbiome, and are implicated in diseases such as inflammatory bowel disease, infections, cancer, and disorders linked to mucosal barrier dysfunction[1][3][5][6]. While drugs like mucolytics can modify mucus properties, "gastrointestinal mucosa and mucoproteins" does not designate a unique molecular therapeutic target but a larger protective system within the GI tract.

Other names
Gastrointestinal mucus systemGastrointestinal mucous membraneGI mucosaMucins (for primary mucoprotein subgroup)
02

Mechanism of action

Mucolytics: reduce mucus viscosity by breaking disulfide bonds in mucoproteins\nPeptide mucolytics: depolymerize DNA/F-actin in hypersecreted mucus (less direct on mucoproteins)

03

Biological functions

Barrier function (protects epithelium from pathogens, mechanical, and chemical injury)Immune defense (hosts immune cells, mediates immunotolerance/response)Lubrication (aids transport of contents)Homeostasis of local microbiota (prevents bacterial invasion, supports symbionts)Nutrient and water absorption (mucosa)
04

Disease associations

Inflammation (e.g., IBD, colitis)Infection (bacterial, parasitic)Cancer (e.g., gallbladder cancer overexpresses mucoproteins)Other (autoimmune disease, fibrosis, abnormal growths/polyps)
05

Safety considerations

Mucolytic therapy may impair protective barrier if overused, increasing infection riskDisruption of mucus/mucosa can expose epithelium to injury/infection
06

Interacting drugs

Mucolytic agents (e.g., N-acetylcysteine, classic/peptide mucolytics)
07

Biomarkers

MUC2 levels (major intestinal mucin)Mucoprotein expression in disease (e.g., gallbladder cancer)

Beyond the preview

Go deeper on Gastrointestinal mucosa and mucoproteins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrointestinal mucosa and mucoproteins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call